Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb

Evotec announces progress in neuroscience collaboration with Bristol Myers Squibb

By, Admin 13 June 2024

Overview

Evotec SE, a life science company, announced that the company has reached important scientific progress within its neuroscience collaboration with Bristol Myers Squibb triggering a research payment of US$ 20 million to Evotec. A target-based programme progresses into late pre-clinical development, further contributing to the fast-growing and promising pipeline of discovery to clinical-stage programmes in neurodegeneration that the partnership has generated.

About This Collaboration

  • Evotec and Bristol Myers Squibb entered their strategic neuroscience collaboration in December 2016 to identify disease-modifying treatments for a broad range of neurodegenerative diseases.
  • Currently approved drugs mainly offer short-term management of the patients’ symptoms and there is a significant unmet medical need for therapeutic modalities that slow down or prevent disease progression.

Studies for EVT8683

  • A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. 
  • Following a successful phase I study Bristol Myers Squibb announced that a phase II study for BMS-986419 is scheduled to commence in 2024. 
  • In March 2023, Bristol Myers Squibb and Evotec extended and expanded this partnership for an additional 8 years.

Words From CSO: Evotec

Dr Cord Dohrmann, chief scientific officer of Evotec, said: “We are excited to further expand our pipeline with another high-potential programme progressing into late pre-clinical development, demonstrating the exceptional productivity of our neuroscience partnership with Bristol Myers Squibb and our shared commitment to innovation and patient care. Together with Bristol Myers Squibb we have been able to advance a growing portfolio of programmes to critical inflection points, bringing us closer to our joint goal of delivering new therapeutic options for patients suffering from devastating neurological disorders.”

Evotec

Evotec is a life science company with a unique business model that delivers on its mission to discover and develop highly effective therapeutics and make them available to the patients.

Optimize Your trial insights with Clival Database.

Are you exhausted from the uncertainty of trial insights pricing? Clival Database ensures the clarity in the midst of the global scenario for clinical trials to you.

Clival Database is one of the best databases that offers an outstanding number of clinical trial data in terms of 50,000+ molecules and from primary regulatory markets as well as new entrants like Indian and Chinese markets.

With Clival, you get accurate positioning of historical sales data, patent database, company profiling, safety & efficacy, and prediction of launch of new innovative molecules helping you to align your research and driving down the cost.

To add value, we further break down our analytics for you so that improving your operational effectiveness; optimizing your clinical trials; and offering you accurate and high-quality data at lowest possible prices becomes possible.

Elevate your trial success rate with the cutting-edge insights from Clival database.

Check it out today and make more informed sourcing decisions! Learn More!